Lactobacillus pentosus and application thereof in prevention and treatment of obesity and / or fat loss

Abstract

The invention discloses lactobacillus pentosus and application thereof in preventing and treating obesity and / or fat loss, and belongs to the technical field of microorganisms. The preservation number of the lactobacillus pentosus pm002 is CCTCC M 2021927, the preservation unit is China Center for Type Culture Collection (CCTCC), Wuhan University, the preservation address is 8th road in Wuchang District, Wuhan City, Hubei Province, and the preservation time is July 23, 2021. An obese animal model induced by a high-fat feed is divided into a control group and a probiotic group. The curative effect of the probiotics is evaluated through differences in four aspects: mouse weight, fat weight, serum index and histochemistry. The lactobacillus pentosus pm002 is proved to be capable of effectively relieving the phenotype of obese mice induced by high fat, which indicates that the lactobacillus pentosus pm002 has the prospect of relieving obesity, and the invention provides a new drug choice and thought for treating obesity.

Description

Technical Field

[0001] The present invention belongs to the technical field of microbiology, and particularly relates to a Lactobacillus pentosus and its application in preventing and treating obesity and / or reducing fat. Background Art

[0002] The incidence of obesity has been gradually soaring, and the related diseases caused by obesity, such as type II diabetes, hyperlipidemia, non-alcoholic fatty liver disease, chronic inflammation, etc., have become a key health issue that society currently focuses on.

[0003] Obesity refers to the pathophysiological changes of the human body caused by excessive accumulation of body fat. According to statistics, it is a chronic disease with a rapidly increasing incidence that is most easily overlooked at present and is accompanied by a variety of serious complications. At present, the treatment methods of obesity mainly include exercise, drug intervention, health care therapy, surgical intervention, etc.

[0004] Research shows that the intestinal microecosystem composition of obese people is different from that of thin people. How to change obesity by adjusting the intestinal microecosystem has become an issue that people are concerned about, and using probiotics to regulate the intestinal microecosystem is one of the methods for preventing and treating obesity. Probiotics can regulate the composition of the intestinal flora, making beneficial bacteria the dominant flora, inhibiting the growth of harmful bacteria and the generation of related metabolites, and participating in the body's immune process, which can effectively relieve obesity symptoms; probiotics may reduce food intake by regulating appetite and satiety. Some probiotics can enhance the production of short-chain fatty acids, enhance fatty acid oxidation, and reduce fat storage; some probiotics of the Bifidobacterium genus can promote the release of glucagon-like peptide-1 (GLP-1), thereby regulating appetite; probiotics may avoid obesity by reducing inflammation in the body; some probiotics can also participate in improving insulin sensitivity. Therefore, probiotics may affect body weight through multiple aspects of the body. Summary of the Invention

[0005] The purpose of the present invention is to provide a Lactobacillus pentosus and its application in preventing and treating obesity and / or reducing fat, and to evaluate the efficacy of probiotics through four aspects of differences: mouse body weight, fat weight, serum indicators, and histochemistry, proving that Lactobacillus pentosus Pm002 can effectively relieve the phenotype of high-fat-induced obese mice and provide new drug options and ideas for the treatment of obesity.

[0006] To achieve the above purpose, the present invention provides the following solutions: The present invention provides a Lactobacillus pentosus ( Lactiplantibacillus pentosus ) pm002, and the preservation number of the Lactobacillus pentosus pm002 is CCTCC M 2021927, the preservation unit: China Center for Type Culture Collection, Wuhan University, the preservation address: Bayi Road, Wuchang District, Wuhan City, Hubei Province, and the preservation time: July 23, 2021.

[0007] The present invention also provides an application of the above-mentioned Lactobacillus pentosus pm002 in preventing and treating obesity and / or reducing fat.

[0008] Furthermore, the Lactobacillus pentosus pm002 prevents and treats obesity by reducing body weight and fat content.

[0009] Furthermore, the Lactobacillus pentosus pm002 prevents and treats obesity by regulating the homeostasis of the intestinal flora.

[0010] Furthermore, the Lactobacillus pentosus pm002 prevents and treats obesity by the contents of serum TG, TC, LDL-C and HDL-C.

[0011] Furthermore, the Lactobacillus pentosus pm002 prevents and treats obesity by reducing liver fat deposition and decreasing epididymal fat cells.

[0012] The present invention also provides a pharmaceutical composition for preventing and treating obesity. The pharmaceutical composition comprises a pharmaceutically effective dose of Lactobacillus pentosus pm002, and the deposit number of Lactobacillus pentosus pm002 is CCTCC M 2021927, the depositary institution: China Center for Type Culture Collection, Wuhan University, the deposit address: Bayi Road, Wuchang District, Wuhan City, Hubei Province, and the deposit date: July 23, 2021.

[0013] Furthermore, the pharmaceutically effective dose is 1×10 9 CFU.

[0014] The present invention discloses the following technical effects: The present invention uses an obese animal model induced by a high-fat diet, which is divided into a control group and a probiotic group. The efficacy of the probiotic is evaluated through four aspects of differences: mouse body weight, fat weight, serum indexes and histochemistry. It is proved that Lactobacillus pentosus pm002 can effectively relieve the phenotype of high-fat-induced obese mice and has a certain therapeutic effect on obesity. The intestinal isolate bacterium Lactobacillus pentosus pm002 can be used as a probiotic preparation. The research shows that Lactobacillus pentosus pm002 has an obvious therapeutic and improving effect on obesity, which indicates that Lactobacillus pentosus pm002 has the prospect of relieving obesity. The present invention provides a new drug option and idea for the treatment of obesity. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the following will briefly introduce the drawings required in the embodiments. Obviously, the drawings in the following description are only some embodiments of the present invention. For those of ordinary skill in the art, without creative efforts, other drawings can also be obtained based on these drawings.

[0016] Figure 1 It is a graph showing the difference in body weight between mice in the high-fat diet + Lactobacillus pentosus pm002 group and those in the high-fat diet group. Among them, the left figure is a comparison graph of the two groups of mice. The mouse on the left is in the high-fat diet + Lactobacillus pentosus pm002 group, and the mouse on the right is in the high-fat diet group. The right figure is a line graph showing the difference in body weight between mice in the high-fat diet + Lactobacillus pentosus pm002 group and those in the high-fat diet group. Figure 2 It is a graph showing the difference in fat between mice in the high-fat diet + Lactobacillus pentosus pm002 group and those in the high-fat diet group. Among them, the left figure is a comparison graph of the two groups of mice, and the right figure is a bar graph showing the comparison of fat weights between mice in the high-fat diet + Lactobacillus pentosus pm002 group and those in the high-fat diet group. Figure 3 It is a comparison graph of the contents of serum TG, TC, LDL-C, and HDL-C between mice in the high-fat diet + Lactobacillus pentosus pm002 group and those in the high-fat diet group. Figure 4 It is a graph showing the histopathological differences between mice in the high-fat diet + Lactobacillus pentosus pm002 group and those in the high-fat diet group. Detailed implementation mode

[0017] Now, various exemplary implementation modes of the present invention will be described in detail. This detailed description should not be considered as a limitation of the present invention, but should be understood as a more detailed description of certain aspects, characteristics, and implementation schemes of the present invention.

[0018] Next, the technical solutions of the present invention will be clearly and completely described in conjunction with specific embodiments. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts shall fall within the scope of protection of the present invention.

[0019] Among them, the deposit number of Lactobacillus pentosus pm002 used in the present invention is CCTCC M 2021927. The depository: China Center for Type Culture Collection, Wuhan University. The deposit address: Bayi Road, Wuchang District, Wuhan City, Hubei Province. The deposit date: July 23, 2021.

[0020] Example 1 (1)Prepare WT mice Purchase 20 8-week-old wild-type BL / C57 male mice from Shanghai Lingchang Company and raise them in the SPF barrier system of the Experimental Animal Center of Shanghai Jiao Tong University. After one week of adaptive feeding, the mice are randomly divided into 2 groups, namely the high-fat diet group (HFD) and the high-fat diet + Lactobacillus pentosus pm002 group. All animals can drink water and eat freely. During the experiment, the 3R principle is followed to give humanitarian care to the experimental animals.

[0021] (2)Lactobacillus pentosus ( Lactiplantibacillus pentosus)Treatment of obese mouse model by intragastric administration of Lactobacillus pentosus pm002 Mice in the high-fat diet group (HFD) and the high-fat diet + Lactobacillus pentosus pm002 group were given a high-fat diet (HFD 60% kcal fat, Research Diets D12492). The feeding time for each group was 18 weeks. During this period, different groups of mice were treated by intragastric administration.

[0022] The cultured Lactobacillus pentosus pm002 bacterial liquid was centrifuged at 4000 rpm for 5 min to collect the bacterial cells, and then the bacteria were resuspended in physiological saline at a final concentration of approximately 5×10 9 CFU / mL. Mice in the high-fat diet + Lactobacillus pentosus pm002 group were treated by intragastric administration at a dose of 200 μL of Lactobacillus pentosus pm002 per mouse (i.e., the dose of Lactobacillus pentosus pm002 was 1×10 9 CFU), and the treatment was repeated every other day for 18 weeks. At the same time, mice in the high-fat diet group were only treated by intragastric administration of physiological saline.

[0023] (3)Detection of experimental indexes of mice 1) Detection of mouse body weight Mice were allowed to eat and drink freely, and their body weights (g) were measured once every 7 days. As shown in the comparison of body weight changes Figure 1 , there was no difference in the initial body weights between the two groups of mice. Starting from the 11th week, the body weight of the high-fat diet group (HFD) was significantly higher than that of the high-fat diet + Lactobacillus pentosus pm002 group. After the experiment, the body weight increments of mice in each group were calculated, and the body weight increment of mice in the high-fat diet + Lactobacillus pentosus pm002 group was significantly lower than that of the high-fat diet group (HFD).

[0024] 2) Determination of mouse fat weight After anesthesia, mice were bled by eye socket enucleation, sacrificed according to the operation standard for dissection, and the perirenal and intra-abdominal fat were taken and weighed for their wet weights (g). As shown in the results Figure 2 , compared with the high-fat diet group (HFD), the perirenal and intra-abdominal fat of mice in the high-fat diet + Lactobacillus pentosus pm002 group were significantly reduced.

[0025] 3) Detection of serum indexes After anesthesia, mice were bled by eye socket enucleation, incubated in a water bath at 37°C for 30 min, and centrifuged at 3000 r / min for 15 min to obtain serum for serum index detection. Using relevant detection kits (all purchased from Nanjing Jiancheng Reagent Co., Ltd.), the contents of serum TG, TC, LDL-C, and HDL-C were detected according to the instructions. As shown in the results Figure 3 , the contents of TC, TG, and LDL-C in the high-fat diet + Lactobacillus pentosus pm002 group were significantly lower than those in the high-fat diet group (HFD), while the content of HDL-C was significantly higher than that in the high-fat diet group (HFD), and the differences were statistically significant.

[0026] 4) Pathological observation After the mice were sacrificed, part of the liver and epididymal fat were taken under sterile conditions. Tissues at the same location were selected for fixation with 4% paraformaldehyde, stained with hematoxylin and eosin (H&E), and the stained sections were observed under an optical microscope to analyze the histopathological differences. The results are as Figure 4 shown. Compared with the high-fat diet group (HFD), the mice in the high-fat diet + L. pentosus pm002 group had less liver fat deposition and significantly smaller epididymal fat cells.

[0027] Therefore, L. pentosus pm002 can regulate the homeostasis of the intestinal flora and prevent and treat obesity. That is, it has the function of inhibiting the growth of harmful intestinal bacteria and regulating the intestinal flora.

[0028] The present invention proves that L. pentosus pm002 has a good effect in preventing and / or treating obesity.

[0029] Of course, the above description is not limited to the above examples. The technical features not described in the present invention can be realized by or adopted from the prior art, and will not be elaborated here: The above embodiments and drawings are only used to illustrate the technical solutions of the present invention and are not a limitation to the present invention. The present invention has been described in detail with reference to the preferred embodiments. Those of ordinary skill in the art should understand that any changes, modifications, additions or substitutions made by those of ordinary skill in the art within the scope of the essence of the present invention do not depart from the spirit of the present invention and should also fall within the scope of the claims of the present invention.

Claims

1. Lactobacillus pentosus ( Lactiplantibacillus pentosus ), pm002, characterized in that The preservation number of the Lactobacillus pentosus pm002 is CCTCC M 2021927, the preservation unit is: China Type Culture Collection, Wuhan University, the preservation address is: Bayi Road, Wuchang District, Wuhan City, Hubei Province, and the preservation time is July 23, 2021.

2. Use of Lactobacillus pentosus pm002 as claimed in claim 1 in preventing and treating obesity and / or reducing fat.

3. Use of Lactobacillus pentosus pm002 according to claim 2 in the prevention and treatment of obesity and / or fat reduction, characterized in that, The Lactobacillus pentosus pm002 prevents and treats obesity by reducing body weight and fat content.

4. The use of Lactobacillus pentosus pm002 in preventing and treating obesity and / or reducing fat according to claim 2, characterized in that The Lactobacillus pentosus pm002 prevents and treats obesity by regulating the homeostasis of intestinal flora.

5. Use of Lactobacillus pentosus pm002 according to claim 2 in the prevention and treatment of obesity and / or fat reduction, characterized in that, The Lactobacillus pentosus pm002 prevents and treats obesity by controlling the contents of serum TG, TC, LDL-C and HDL-C.

6. Use of Lactobacillus pentosus pm002 according to claim 2 in the prevention and treatment of obesity and / or fat reduction, characterized in that, The Lactobacillus pentosus pm002 prevents and treats obesity by reducing liver fat deposition and reducing epididymal fat cells.

7. A pharmaceutical composition for preventing and treating obesity, characterized in that: The pharmaceutical composition includes a pharmaceutically effective dose of Lactobacillus pentosus pm002, the preservation number of the Lactobacillus pentosus pm002 is CCTCC M 2021927, the preservation unit is: China Type Culture Collection, Wuhan University, the preservation address is: Bayi Road, Wuchang District, Wuhan City, Hubei Province, and the preservation time is July 23, 2021.

8. The pharmaceutical composition according to claim 6, wherein The pharmaceutically effective dose is 1×10 9 CFU.

Images